{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["91"],"submitter":["Han JK"],"funding":["Biotronik"],"pubmed_abstract":["Background
The HOST-IDEA trial demonstrated non-inferiority of 3-to-6-month dual antiplatelet therapy (DAPT) to 12-month DAPT for net adverse clinical event (NACE) at 1 year in patients undergoing percutaneous coronary intervention (PCI) with third-generation drug-eluting stents (DES). We evaluated the long-term outcomes of abbreviated antiplatelet therapy following PCI with third-generation DES.Methods
In the open-label, adjudicator-blinded, multicentre, randomised HOST-IDEA trial, 2013 patients from 37 hospitals in South Korea were randomly allocated to 3-to-6-month (n = 1002) or 12-month (n = 1011) DAPT between January 2016 and May 2021. The primary outcome was NACE at 3 years, comprising cardiac death, target vessel myocardial infarction (TVMI), clinically driven target"],"journal":["EClinicalMedicine"],"pagination":["103698"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12774699"],"repository":["biostudies-literature"],"pubmed_title":["Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with ultrathin-strut drug-eluting stents in South Korea: 3-year outcomes of the multicentre, randomised HOST-IDEA trial."],"pmcid":["PMC12774699"],"pubmed_authors":["Shin S","Kim SY","Lee N","Kang HJ","Park K","Lee SJ","Han SH","Kim HS","Han JK","Yang HM","Kim JW","Hur SH","Park KW","Kim SH","Hwang D","Koo BK","Kim W","Park SH","Kang J","Yang S"],"additional_accession":[]},"is_claimable":false,"name":"Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with ultrathin-strut drug-eluting stents in South Korea: 3-year outcomes of the multicentre, randomised HOST-IDEA trial.","description":"Background
The HOST-IDEA trial demonstrated non-inferiority of 3-to-6-month dual antiplatelet therapy (DAPT) to 12-month DAPT for net adverse clinical event (NACE) at 1 year in patients undergoing percutaneous coronary intervention (PCI) with third-generation drug-eluting stents (DES). We evaluated the long-term outcomes of abbreviated antiplatelet therapy following PCI with third-generation DES.Methods
In the open-label, adjudicator-blinded, multicentre, randomised HOST-IDEA trial, 2013 patients from 37 hospitals in South Korea were randomly allocated to 3-to-6-month (n = 1002) or 12-month (n = 1011) DAPT between January 2016 and May 2021. The primary outcome was NACE at 3 years, comprising cardiac death, target vessel myocardial infarction (TVMI), clinically driven target","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T13:11:55.351Z","creation":"2026-05-30T03:11:38.182Z"},"accession":"S-EPMC12774699","cross_references":{"pubmed":["41509615"],"doi":["10.1016/j.eclinm.2025.103698"]}}